Defining stroma function in the developing tumour microenvironment

Immunotherapy only works for a minority of cancer patients because tumours actively switch off the immune system, and scientists are now tracing how a specific type of non-cancer cell called the cancer-associated fibroblast helps them do it. The problem is that while immunotherapy has transformed treatment for some cancers, most patients still do not respond. Tumours are not just clumps of malignant cells—they contain a supporting cast of normal cells that the cancer hijacks. Cancer-associated fibroblasts are emerging as key players in this sabotage, but researchers do not yet know exactly how, when, or on which immune cells they act. This programme uses advanced technologies to map the molecular networks that give these fibroblasts their suppressive power. If the team succeeds in uncoupling these networks, the findings could lead to new or improved cancer therapies that make immunotherapy effective for far more patients. This is fundamental science—it will not produce a drug tomorrow. But understanding how a tumour builds its own protective environment is the kind of mechanistic insight that has historically opened entirely new treatment avenues, much as discovering immune checkpoints did a decade ago.